Anticoagulation for DVT in End-Stage Renal Disease
Immediate Treatment Recommendation
- The American College of Chest Physicians recommends initiating unfractionated heparin (UFH) as the preferred anticoagulant in patients with DVT and ESRD, either as intravenous infusion or fixed-dose subcutaneous administration, followed by warfarin bridging to achieve therapeutic INR 2.0-3.0 1, 2
Rationale for UFH Over Other Anticoagulants
- Low-molecular-weight heparin (LMWH) and fondaparinux are retained in patients with renal impairment and should be avoided in ESRD, according to the American College of Chest Physicians 2, 3
- UFH is not renally cleared, making it the safest option with predictable pharmacodynamics in ESRD, as recommended by the American College of Chest Physicians 2
Specific UFH Dosing Regimens
- The American College of Chest Physicians recommends initiating IV UFH with standard weight-based dosing protocols and monitoring with aPTT to maintain therapeutic range 1, 2
Warfarin Bridging Strategy
- The American College of Chest Physicians recommends starting warfarin on day 1 simultaneously with UFH, and continuing parenteral UFH for minimum 5 days AND until INR ≥2.0 for at least 24 hours 1, 2
- The target INR range is 2.0-3.0 (target 2.5), as recommended by the American College of Chest Physicians 3
Treatment Duration
- The American College of Chest Physicians recommends treating provoked DVT for exactly 3 months, then stopping, and treating unprovoked DVT for a minimum of 3 months, then reassessing for extended anticoagulation 4
Treatment Setting
- The American College of Chest Physicians recommends home treatment over hospitalization if the patient has adequate home circumstances, including well-maintained living conditions, strong family/friend support, phone access, and ability to return quickly if deterioration occurs 2, 5
Critical Caveats and Pitfalls
- The American College of Chest Physicians recommends avoiding LMWH or fondaparinux in ESRD, as these agents accumulate unpredictably and increase bleeding risk 2, 3
- If recurrent VTE occurs on therapeutic warfarin, the American College of Chest Physicians recommends reassessing warfarin dosing and INR control, or considering increasing target INR range with careful monitoring, rather than switching to LMWH 4